The Rise and Rise of China's Pioneering Dual Antibodies
03 Jun 2024
Phase 3Clinical ResultASCOImmunotherapyADC
In the ever-evolving world of pharmaceutical innovation, the spotlight has once again turned to China's homegrown biopharmaceutical companies. Recently, Akeso Biopharma has been making waves with its groundbreaking cancer treatment, AK112 - a dual PD-1/VEGF inhibitorPD-1/VEGF inhibitor.
On May 24th, Akeso Biopharma presented the highly anticipated Phase III data for AK112 at the American Society of Clinical Oncology (ASCO) conference. While the results were not considered "spectacular" by market standards, they still demonstrated AK112's promising efficacy in treating EGFR-positive non-small cell lung cancer (NSCLC). The objective response rate (ORR) was 50.6% and the median progression-free survival (mPFS) was 7.06 months.
However, the real excitement came a week later, on May 31st, when Kangway announced that AK112 had outperformed Merck's Keytruda (pembrolizumab) in a head-to-head Phase III trial for first-line NSCLC treatment. This landmark achievement solidified AK112's position as a formidable challenger in the highly competitive immunotherapy landscape.
The market reacted enthusiastically to this news, with Kangway's stock price soaring by as much as 87% to reach a new three-year high of HK$60 per share. This rollercoaster of events has certainly left investors' emotions in a state of flux, as they grapple with the rapid rise and fall of Kangway's fortunes.
The success of AK112 is not just a testament to Kangway's scientific prowess, but also a reflection of China's growing capabilities in the biopharmaceutical industry. The company's pipeline already includes three approved products - Kaduneli, Paiapili, and AK112 - demonstrating its ability to bring innovative therapies to market.
As the competition in the NSCLC treatment landscape intensifies, with the emergence of promising antibody-drug conjugates (ADCs) like Merck's TROP2-ADC, Kangway will need to continue to innovate and outperform its rivals. The future of AK112 and its potential combination with other novel therapies will be a captivating storyline to follow in the years to come.
The rise of China's homegrown biopharmaceutical champions, like Kangway, is a testament to the country's commitment to fostering a vibrant and innovative pharmaceutical ecosystem. As the industry continues to evolve, the world will be watching to see how many more "legends" these pioneering companies can create.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.